Is monthly retreatment with intravitreal bevacizumab (Avastin) necessary in neovascular age-related macular degeneration?
OBJECTIVE
To report our short-term experience with bevacizumab in neovascular age-related macular degeneration (AMD) and recommend a new treatment strategy.


METHODS
Retrospective chart review of 29 consecutive patients receiving 1.25 mg of intravitreal bevacizumab for AMD and completing 12 weeks of follow up. Outcome measures were best corrected visual acuity (BCVA) and optical coherence tomography (OCT) central macular thickness. Injections were repeated if no further improvement was observed.


RESULTS
Twenty-nine eyes of 29 patients were included. The average BCVA improved from 20/148 at baseline to 20/106 at twelve weeks (P = 0.041). Of the 29 eyes, 25 (86.2%) had stable or improved BCVA. Average mean central macular thickness measured by OCT improved from 351 mum at baseline to 278 mum at 12 weeks (P = 0.003). Stabilization of vision and improved OCT central macular thickness were maintained for at least eight weeks following only a single injection in the majority of eyes. During the three months of follow up, only five eyes (17.2%) required repeat injections, with only three (10.3%) requiring retreatment at eight weeks and none at four weeks. No significant ocular or systemic side effects were observed.


CONCLUSIONS
This short-term data suggests that bevacizumab appears to be a safe and effective treatment for neovascular AMD. Injections as frequent as every month do not appear to be necessary since initial treatment effect appears to be maintained for at least eight weeks in almost all of our patients.
Ghazi
Nicola G
NG
Department of Ophthalmology, University of Virginia Health System, Charlottesville, VA, USA.
Kirk
Tyler Q
TQ
Knape
Robert M
RM
Tiedeman
James S
JS
Conway
Brian P
BP
JAMA. 2005 Mar 23;293(12):1509-13
15784876
Am J Ophthalmol. 2006 Jul;142(1):1-9
16815245
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
Toxicol Pathol. 1999 Sep-Oct;27(5):536-44
10528633
Retina. 2006 Mar;26(3):270-4
16508425
Ophthalmology. 2006 Mar;113(3):363-372.e5
16458968
Toxicol Sci. 1999 Nov;52(1):101-6
10568703
Retina. 2006 Mar;26(3):262-9
16508424
Am J Ophthalmol. 2006 Jul;142(1):162-4
16815270
Retina. 2006 Mar;26(3):257-61
16508423
Retina. 2006 May-Jun;26(5):495-511
16770255
Br J Ophthalmol. 2007 Feb;91(2):157-60
16870653
Retina. 2006 May-Jun;26(5):512-8
16770256
N Engl J Med. 2004 Dec 30;351(27):2805-16
15625332
Br J Ophthalmol. 2006 Nov;90(11):1344-9
16854824
Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1601-8
19597740
Ophthalmology. 2005 Jun;112(6):1035-47
15936441
Retina. 2006 Apr;26(4):383-90
16603955
Ophthalmology. 2006 Apr;113(4):633.e1-4
16483659